RxDoctor Payments Data

Galina Sabir, MD

Cardiovascular Disease · Chicago, ILNPI 1447439062

Payments from drug & device makers

$3,430in general payments, 2019–2025

Across 162 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$774
  • Boehringer Ingelheim$567
  • Novartis$499
  • Pfizer$414
  • Amarin Pharma, Inc.$285
  • AstraZeneca$268
  • plus $624 from 12 others

What the payments were for

  • Food & beverage$3,40899%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,430 in reported general payments places this provider in the 60th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$380,372
Medicare patients
150
Services billed
5,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin130$145,062
EliquisApixaban51$66,359
EntrestoSacubitril/Valsartan40$60,431
VascepaIcosapent Ethyl87$54,198
JanuviaSitagliptin Phosphate28$42,355
FarxigaDapagliflozin Propanediol31$42,010
XareltoRivaroxaban19$25,065
TrulicityDulaglutide22$24,598
LinzessLinaclotide31$22,755
CreonLipase/Protease/Amylase11$19,286
TradjentaLinagliptin28$18,523
Breo ElliptaFluticasone/Vilanterol20$8,324
Icosapent Ethyl17$6,651
Diclofenac Sodium46$4,607
Nifedipine ErNifedipine108$3,820

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$567$163,585158 claims
PfizerEliquis$414$66,35951 claims
NovartisEntresto$499$60,43140 claims
MerckJanuvia$215$42,35528 claims
AstraZenecaFarxiga$268$42,01031 claims
Johnson & JohnsonXarelto$774$25,06519 claims
GSKBreo Ellipta$39$8,32420 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →